You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

DIPENTUM Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Dipentum patents expire, and when can generic versions of Dipentum launch?

Dipentum is a drug marketed by Mylan Spclt Viatris and is included in one NDA.

The generic ingredient in DIPENTUM is olsalazine sodium. There are five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the olsalazine sodium profile page.

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for DIPENTUM?
  • What are the global sales for DIPENTUM?
  • What is Average Wholesale Price for DIPENTUM?
Summary for DIPENTUM
Drug patent expirations by year for DIPENTUM
Drug Prices for DIPENTUM

See drug prices for DIPENTUM

Pharmacology for DIPENTUM
Drug ClassAminosalicylate

US Patents and Regulatory Information for DIPENTUM

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan Spclt Viatris DIPENTUM olsalazine sodium CAPSULE;ORAL 019715-001 Jul 31, 1990 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for DIPENTUM

See the table below for patents covering DIPENTUM around the world.

Country Patent Number Title Estimated Expiration
Netherlands 930101 ⤷  Sign Up
Japan S56154417 USE OF 3,3'-AZOBIS -(6-HYDROXYBENZOIC ACID) AS DRUG AND PHARMACEUTICAL COMPOSITION CONTAINING IT ⤷  Sign Up
Japan H0148247 ⤷  Sign Up
Australia 6862481 ⤷  Sign Up
Canada 1179602 APPLICATION PHARMACOLOGIQUE DE L'ACIDE 3,3'-AZO-BIS- 6-HYDROXYBENZOIQUE ET COMPOSES PHARMACEUTIQUES LE CONTENANT (USE OF 3,3'-AZO-BIS-(6-HYDROXY BENZOIC ACID) AS A DRUG AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME) ⤷  Sign Up
Germany 3161216 ⤷  Sign Up
Australia 549237 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.